Company Description
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.
The company’s lead product is naporafenib which is in SEACRAFT-2 pivotal Phase 3 trial for patients with NRAS-mutated (NRASm) melanoma; and in SEACRAFT-1 Phase 1b trial for patients with NRAS Q61X melanoma.
It also develops ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-altered solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-altered solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGRF and RAS/MAPK solid tumors.
In addition, the company’s products under development include ERAS-801, a central nervous system (CNS)-penetrant EGFR inhibitor for patients with EGFR-altered recurrent glioblastoma (GBM) which is in phase 1 clinical trials; and ERAS-007, an oral inhibitor of ERK1/2 and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors.
It has a license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds.
Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
| Country | United States |
| Founded | 2018 |
| IPO Date | Jul 16, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 103 |
| CEO | Jonathan Lim |
Contact Details
Address: 3115 Merryfield Row, Suite 300 San Diego, California 92121 United States | |
| Phone | 858 465 6511 |
| Website | erasca.com |
Stock Details
| Ticker Symbol | ERAS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001761918 |
| CUSIP Number | 29479A108 |
| ISIN Number | US29479A1088 |
| Employer ID | 83-1217027 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jonathan E. Lim M.D. | Co-Founder, Chairman and Chief Executive Officer |
| Dr. David M. Chacko M.D. | Chief Financial Officer and Chief Business Officer |
| Dr. Michael D. Varney Ph.D. | Chairman of Research and Development, Scientific Advisory Board Member and Director |
| Dr. Shannon R. Morris M.D., Ph.D. | Chief Medical Officer |
| Dr. Nik Chetwyn Ph.D. | Chief Operating Officer |
| Ebun S. Garner Esq., J.D. | General Counsel and Corporate Secretary |
| Dr. Lisa Tesvich-Bonora Ph.D. | Chief People Officer |
| Brian L. Baker CPA, M.S. | Senior Vice President of Finance |
| Chandra D. Lovejoy M.S. | Chief Regulatory Affairs Officer |
| Dr. Robert Shoemaker Ph.D. | Senior Vice President of Research |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 13, 2025 | 10-Q | Quarterly Report |
| May 13, 2025 | 8-K | Current Report |
| Apr 29, 2025 | ARS | Filing |
| Apr 29, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 15, 2025 | 144 | Filing |
| Mar 20, 2025 | 10-K | Annual Report |
| Mar 20, 2025 | 8-K | Current Report |
| Mar 17, 2025 | 144 | Filing |
| Feb 18, 2025 | 144 | Filing |